Premium
Pyrazolylborat‐Zinkkomplexe mit Medikament‐Liganden
Author(s) -
Hartmann Uwe,
Vahrenkamp Heinrich
Publication year - 1994
Publication title -
chemische berichte
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 0009-2940
DOI - 10.1002/cber.19941271207
Subject(s) - chemistry , carboxylate , denticity , medicinal chemistry , chelation , zinc , ligand (biochemistry) , hydrolysis , tris , stereochemistry , inorganic chemistry , crystal structure , crystallography , organic chemistry , biochemistry , receptor
Pyrazolylborate‐Zinc Complexes with Drugs as Ligands The model complexes for hydrolytic zinc enzymes L 3 Zn‐OH with L 3 a = tris(3‐ tert ‐butyl‐5‐methylpyrazolyl)borate and L 3 b = tris(3‐cumyl‐5‐methylpyrazolyl)borate ( 1a, b ) were tested for their interaction with drugs. With acetazolamide (HAcm) the complex L 3 b Zn‐Acm ( 2b ) is obtained which according to a structure determination contains the Acm ligand chelating by one azole and the sulfonamide nitrogen atoms. Furosemide (HFur) forms the two complexes L 3 Zn‐Fur ( 3 ) which according to their spectra contain the furosemide anion as a monodentate carboxylate ligand. Aspirin (AcSalH) is saponified by both L 3 Zn‐OH complexes yielding L 3 Zn‐Sal ( 4 ). The structure determination of L 3 b Zn‐Sal ( 4b ) has shown the salicylic acid to be bound as a monodentate carboxylate as well.